BMY Q4 2025 Earnings Analysis

Welcome to Beta Finch, your AI-powered earnings breakdown where we decode quarterly reports so you don't have to. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're diving into Bristol Myers Squibb's Q4 2025 earnings call - and let me tell you, this one was packed with updates. But first, Jordan, I need to get our mandatory disclaimer out of the way. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

Absolutely. So Q4 revenue came in flat year-over-year at about $12.5 billion, but here's the key detail that investors need to understand - their growth portfolio, which includes all their newer drugs, grew 15% in the quarter and represented nearly 60% of total revenue. That's a massive shift from where this company was just a few years ago.

Let's talk about some of those growth drivers. Reblozyl, their blood disorder treatment, crossed $2 billion in annual sales. Breyanzi, their CAR-T cell therapy, grew 47% in Q4. And then you have Camzyos for heart disease growing 57%. These aren't just incremental gains - these are blockbuster-level products hitting their stride.

Jordan, let's break down that pipeline because it spans multiple therapeutic areas. You've got Milvexian for atrial fibrillation and stroke prevention - that's a massive market where they're trying to compete with their own Eliquis. Then there's admilparent for lung fibrosis, and several multiple myeloma treatments. This isn't just one bet - it's a diversified portfolio of shots on goal.

That's a fascinating strategy. CFO David Elkins explained that the roughly 40% price reduction actually helps them competitively because it removes inflationary penalties that had been building up over years. It's counterintuitive - lower prices leading to higher growth - but it makes sense when you understand the complex rebate structures in pharma.

Let's talk about their cost management because this is where Bristol Myers is really showing discipline. They delivered $1 billion in cost savings in 2025 and expect another billion over 2026-2027. But here's the smart part - they're reinvesting some of those savings into growth initiatives like their partnership with BioNTech on pemiglatinib.

The Q&A session had some interesting moments. Analysts were clearly excited about the pipeline density. One analyst noted it's been "a long time" since Bristol Myers had this many pivotal catalysts coming. There was also discussion about business development priorities, with management emphasizing they don't need to "chase deals" given their strong late-stage pipeline position.

For 2026 guidance, they're projecting revenue between $46-47.5 billion with earnings per share of $6.05-6.35. That revenue range reflects continued strength in growth products offset by accelerating declines in legacy assets.

Exactly. And let's not forget they're maintaining their dividend while continuing to invest in R&D. They paid down $10 billion in debt ahead of schedule, so they have financial flexibility for business development if attractive opportunities arise.

One thing that impressed me was management's focus on what they call their "say-to-do ratio" - essentially delivering on commitments. In pharma, where timelines often slip and studies fail, that kind of execution discipline is valuable.

The risk, of course, is that clinical trials are inherently uncertain. But with six shots on goal in 2026 alone, they don't need every program to succeed - just enough to sustain growth momentum.

Thanks for tuning in to Beta Finch. Bristol Myers Squibb is clearly in a transition phase, but the early signs suggest they're executing well on their transformation strategy. We'll be watching those pipeline readouts closely in the second half of 2026.

See you next episode!